Press Releases

Date Title and Summary View
Toggle Summary MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
Independent Data Monitoring Committee R ecommends C ontinuation of the Study with N o   C hanges to Study Sample Size No Safety Concerns Identified Full Study   Enrollment Expected by Year-End 2021; D ata R eadout E xpected in t he F irst H alf of 2022 YAVNE, Israel , July 28, 2021 (GLOBE NEWSWIRE)
View HTML
Toggle Summary MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel , July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for
View HTML
Toggle Summary MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns
Primary Endpoints Met with Highly Statistically Significant Results Compared with Standard-of-Care YAVNE, Israel , July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair
View HTML
Toggle Summary MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal
Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and   D iabetic F oot U lcers Interim Assessment of Ongoing U.S.   Phase II Adaptive Design Study in Venus Leg Ulcers Expected End of July 2021 YAVNE, Israel , July 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd.
View HTML
Toggle Summary MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy YAVNE, Israel , June 29, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair
View HTML
Toggle Summary MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 YAVNE, Israel , June 09, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and
View HTML
Toggle Summary MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal
Findings Provide Preliminary Proof-of-Concept Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin in Second Quarter 2021, with Data Expected by the End of 2021 YAVNE, Israel , June 07, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical
View HTML
Toggle Summary MediWound Reports First Quarter 2021 Financial Results
First Quarter Revenues of $5.8 Million , an Increase of 32% Year-over-Year Conference call begins today at 8:30 am ET   YAVNE, Israel , May 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions
View HTML
Toggle Summary MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first
View HTML
Toggle Summary MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx
Data Expected Second-Half 2021 YAVNE, Israel , April 22, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it has enrolled the first patient
View HTML